Loading...
Market
How many countries will adopt generic lenacapavir by 2025?
2
Resolution / Starting Odds
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
Global health reports and Gilead's official data
Story
Gilead's Lenacapavir: Science's 2024 Breakthrough for HIV Prevention
Dec 13, 2024, 07:30 AM
Gilead Sciences' lenacapavir, a long-acting injectable drug for HIV prevention, has been named the 2024 Breakthrough of the Year by the journal Science. Lenacapavir, which requires only a single shot every six months, demonstrated near-perfect efficacy in clinical trials, preventing HIV infections in 99.9% of participants. The drug targets the HIV capsid, disrupting key stages of viral replication, offering a novel mechanism of action. This development is seen as a significant step towards reducing the global HIV/AIDS epidemic. However, the high cost of lenacapavir poses a potential barrier to its widespread use, particularly in low-income regions. Gilead has made agreements to produce generic versions for 120 of the world's poorest countries, but middle-income nations like Brazil are excluded, sparking concerns about access and affordability.
View original story
Similar markets
Less than 50 • 25%
50 to 80 • 25%
81 to 120 • 25%
More than 120 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%